Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development
Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.
1. A method for promoting the gut health of an infant mammal subject, comprising the steps of:
a) providing an infant formula composition comprising nicotinamide riboside (NR, I), and optionally one or more nicotinyl riboside compounds selected from the group consisting of nicotinic acid riboside (NAR, II), reduced nicotinamide riboside (NRH, IV), reduced nicotinic acid riboside (NARH, V), nicotinamide riboside triacetate (NRTA, VI), nicotinic acid riboside triacetate (NARTA, VII), reduced nicotinamide riboside triacetate (NRH-TA, VIII), and reduced nicotinic acid riboside triacetate (NARH-TA, IX); and
b) orally administering the infant formula composition to the infant mammal subject daily;
wherein the total amount of the nicotinamide riboside and optional one or more nicotinyl riboside compounds is from about 1 μg to about 600 μg per 100 kilocalories of the infant formula composition.
2. The method of claim 1 , wherein the mammal is selected from the group consisting of human, horse, pig, and dog.
3. The method of claim 2 , wherein the mammal is a human.
4. The method of claim 1 , wherein the administering step (b) is performed for at least 1 week, and wherein the level of fecal butyric acid increases by at least 25 parts per million following one week of daily administration of the infant formula composition.
5. The method of claim 4 , wherein the level of fecal propionic acid increases by at least 35 parts per million following one week of daily administration of the infant formula composition.
6. A method for reducing gastrointestinal inflammation in an infant mammal subject, comprising the steps of:
a) providing an infant formula composition comprising nicotinamide riboside (NR, I), and optionally one or more nicotinyl riboside compounds selected from the group consisting of nicotinic acid riboside (NAR, II), reduced nicotinamide riboside (NRH, IV), reduced nicotinic acid riboside (NARH, V), nicotinamide riboside triacetate (NRTA, VI), nicotinic acid riboside triacetate (NARTA, VII), reduced nicotinamide riboside triacetate (NRH-TA, VIII), and reduced nicotinic acid riboside triacetate (NARH-TA, IX); and
b) orally administering the infant formula composition to the infant mammal subject daily;
wherein the total amount of the nicotinamide riboside and optional one or more nicotinyl riboside compounds is from about 1 μg to about 600 μg per 100 kilocalories of the infant formula composition.
7. The method of claim 6 , wherein the mammal is selected from the group consisting of human, cow, horse, pig, and dog.
8. The method of claim 7 , wherein the mammal is a human.
9. The method of claim 6 , wherein the level of fecal butyric acid increases by at least 25 parts per million following one week of daily administration of the infant formula composition.
10. The method of claim 9 , wherein the administering step (b) is performed for at least 1 week, and wherein the level of fecal propionic acid increases by at least 35 parts per million following one week of daily administration of the infant formula composition.